Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Avidity Biosciences, Inc. (RNA)
Company Research
Source: Yahoo! Finance
All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 49%. Earnings per share (EPS) exceeded analyst estimates by 9.1%. Looking ahead, revenue is forecast to grow 74% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are up 12% from a week ago. It is worth noting though that we have found 2 warning signs for Avidity Biosciences (1 makes us a bit uncomfortable!) that you need to take into consideration. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitut
Show less
Read more
Impact Snapshot
Event Time:
RNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNA alerts
High impacting Avidity Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RNA
News
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $65.00 price target on the stock.MarketBeat
- Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.MarketBeat
- Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology InnovationsPR Newswire
- Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
RNA
Earnings
- 8/9/24 - Beat
RNA
Sec Filings
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- 11/14/24 - Form SC
- RNA's page on the SEC website